Palvella Therapeutics (NASDAQ:PVLA) Reaches New 52-Week High – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $127.69 and last traded at $124.45, with a volume of 470889 shares trading hands. The stock had previously closed at $87.84.

Analyst Ratings Changes

PVLA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday. Cantor Fitzgerald boosted their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Truist Financial raised their price target on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Finally, TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $158.69.

Palvella Therapeutics Stock Up 30.9%

The firm has a market cap of $1.36 billion, a P/E ratio of -43.72 and a beta of -0.16. The business’s 50 day moving average is $91.58 and its 200-day moving average is $77.95.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of PVLA. Archer Investment Corp acquired a new stake in Palvella Therapeutics during the third quarter valued at approximately $28,000. Group One Trading LLC grew its position in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $37,000. Finally, JPMorgan Chase & Co. raised its position in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.